Clinical Trial Update: A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19 [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study of FP-025 in severe to critical COVID-19 with ARDS was terminated; results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• FP-025

Snippet

Sponsor: Foresee Pharmaceuticals Co., Ltd. | Conditions: Severe to Critical COVID 19 With Associated ARDS | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2024-01-05